Compare
Baxter International Inc vs Becton Dickinson & Co vs ResMed Inc vs 3M Co
| Latest fiscal year | Baxter International Inc BAX | Becton Dickinson & Co BDX | ResMed Inc RMD | 3M Co MMM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-09-30 | 2026-06-30 | 2025-12-31 |
| Revenue | $11.24B | $21.84B | $5.65B | $24.95B |
| Revenue growth (YoY) | +5.7% | +8.2% | +9.9% | +1.5% |
| Gross margin | 30.1% | 45.4% (computed) | 61.1% | 39.9% (computed) |
| Operating margin | -2.7% | 11.8% | 33.4% | 18.6% |
| Net margin | -8.5% | 7.7% | 26.9% | 13.0% |
| Net income | -$957.00M | $1.68B | $1.52B | $3.25B |
| EPS (Diluted) | -$1.87 | $5.82 | $10.43 | $6.00 |
| Operating cash flow | $845.00M | $3.43B | $1.81B | $2.31B |
| Free cash flow | $332.00M | $2.67B | $1.65B | $1.40B |
| Cash & equivalents | $1.97B | $641.00M | $1.47B | n/a |
| Total assets | $20.05B | $55.33B | $8.97B | $37.73B |
| Total liabilities | $13.95B | n/a | $2.38B | $32.99B |
| Shareholders' equity | $6.10B | $25.39B | $6.59B | $4.75B |
| Return on year-end equity | -15.7% | 6.6% | 23.1% | 68.5% |
| Shares outstanding | n/a | n/a | 144.24M | 530.28M |
Revenue, most recent five fiscal years
| Fiscal year | Baxter International Inc | Becton Dickinson & Co | ResMed Inc | 3M Co |
|---|---|---|---|---|
| Latest | $11.24B Ended 2025-12-31 | $21.84B Ended 2025-09-30 | $5.65B Ended 2026-06-30 | $24.95B Ended 2025-12-31 |
| 1 year earlier | $10.64B Ended 2024-12-31 | $20.18B Ended 2024-09-30 | $5.15B Ended 2025-06-30 | $24.57B Ended 2024-12-31 |
| 2 years earlier | $10.36B Ended 2023-12-31 | $19.37B Ended 2023-09-30 | $4.69B Ended 2024-06-30 | $24.61B Ended 2023-12-31 |
| 3 years earlier | $10.06B Ended 2022-12-31 | $18.87B Ended 2022-09-30 | $4.22B Ended 2023-06-30 | $26.16B Ended 2022-12-31 |
| 4 years earlier | $12.15B Ended 2021-12-31 | $19.13B Ended 2021-09-30 | $3.58B Ended 2022-06-30 | $35.35B Ended 2021-12-31 |